GVS assessment of trientine dihydrochloride (Cufence®) for the treatment of Wilson’s disease
The National Health Care Institute has completed its assessment whether trientine dihydrochloride (Cufence®) can be included in the Medicine Reimbursement System (GVS). The National Health Care Institute recommends to include trientine dihydrochloride (Cufence®) in the GVS on list 1A in a new cluster to be formed together with trientine tetrahydrochloride (Cuprior®).
Registered indication
Trientine dihydrochloride (Cufence®) is indicated for the treatment of Wilson’s disease.
The National Health Care Institute's advice
Based on the considerations mentioned in the report, National Health Care Institute advises to include trientine dihydrochloride (Cufence®) in the GVS on list 1A in a new cluster to be formed together with trientine tetrahydrochloride (Cuprior®). The standard dose of Cufence® can be determined at 800 mg and that of Cuprior® at 450 mg.
The reimbursement of trientine is subject to a further condition.
The present terms of reimbursement are as follows.
124. Trientine
Condition
To be used exclusively for insured persons with Wilson’s disease for whom therapy with D-penicillamine at the maximum tolerated dose is not sufficient.
These further conditions also apply to Cufence®; the text on List 2 can therefore remain unchanged.